Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.

Emily Field, Barclays head of European pharmaceutical research, joins 'Squawk Box' to discuss the state of the weight loss drug market, disappointing trial results of Novo Nordisk's experimental ...

Few (if any) companies have a more attractive pipeline in this field than Novo Nordisk. True, one of the drugmaker's leading candidates, CagriSema, recently failed to impress investors in a phase ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in response to this news. The drug-maker’s own target was higher and market ...